Company / R&D Expense
Stoke Therapeutics, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$137.9M
FY2025
5-year range
$54.2M / $137.9M
FY2021-FY2025
Trend
+67.7%
vs FY2024
Sector context
#110 of 210
Health Care
What the data says
At $138M, Stoke Therapeutics, Inc.'s r&d expense ranks #110 of 210 in the Health Care sector. R&D Expense has increased for 3 consecutive years, from $54M in FY2022 to $138M in FY2025.
Based on SEC 10-K filings.
$138M in FY2025 with a 5-year CAGR of +33.8%.
Improved from $78M to $138M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +36.6%
- 5-Year CAGR
- +33.8%
- 10-Year CAGR
- -
Sector benchmark
#110 of 210 in Health CareTop 52% of 210This company $137.9M Sector average $644.1M
▼
-78.6% below sector average
Key checks
Key Insights
- Stoke Therapeutics, Inc.'s r&d expense has grown for 3 consecutive years.
- 5-year CAGR of +33.8%, indicating consistent growth.
- In FY2025, r&d expense increased 67.7% year-over-year.
- Ranks #110 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $137.9M | +67.7% |
| FY2024 | $82.2M | +5.6% |
| FY2023 | $77.8M | +43.7% |
| FY2022 | $54.2M | +0.0% |
| FY2021 | $54.2M | +68.2% |
| FY2020 | $32.2M | +35.5% |
| FY2019 | $23.8M | +183.9% |
| FY2018 | $8.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026